Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gaush Meditech Ltd. ( (HK:2407) ) has issued an update.
Gaush Meditech Ltd. has scheduled a board meeting for March 26, 2026 to review and approve the Group’s annual results for the financial year ended December 31, 2025. The board will also consider the publication of these results and the potential recommendation of a final dividend, signaling preparations for the company’s year-end financial reporting cycle and possible shareholder returns.
The announcement confirms the current composition of the board, including the chairman, several executive directors, one non-executive director and three independent non-executive directors. This structure underscores the company’s adherence to corporate governance practices expected of Hong Kong–listed issuers as it approaches a key performance disclosure and capital allocation decision point.
The most recent analyst rating on (HK:2407) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Gaush Meditech Ltd. stock, see the HK:2407 Stock Forecast page.
More about Gaush Meditech Ltd.
Gaush Meditech Ltd. is a Cayman Islands–incorporated company listed on the Hong Kong Stock Exchange. The company operates through a group structure, with a board comprising executive, non-executive and independent non-executive directors overseeing its medical technology-related business and corporate governance for shareholders and other stakeholders.
Average Trading Volume: 33,675
Technical Sentiment Signal: Sell
Current Market Cap: HK$766.1M
For detailed information about 2407 stock, go to TipRanks’ Stock Analysis page.